Skip to main content
U.S. flag

An official website of the United States government

Dipotassium N-stearoyltyrosinate ameliorated pathological injuries in triple-transgenic mouse model of Alzheimer's disease

Bibliographic

Year of Publication:
2016
Contact PI Name:
Ze-Jian Wang
Contact PI Affiliation:
School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China
Co-Authors:
Sha Liu, Shuang-Qi Tang, Heng-Jing Cui, Sha Yin, Ming Yin, Hong Zhao, Ling-Hua Meng, Yang Lu
Primary Reference (PubMED ID):
Funding Source:
National Natural Science Foundation of China
Science and Technology Commission of Shanghai Municipality
Study Goal and Principal Findings:

Recently, anandamide (AEA) analogues have been well recognized for its potent neuroprotective effects in counteracting the deterioration of Alzheimer's disease (AD) brains through multiple pathological processes. In previous studies, dipotassium N-stearoyltyrosinate (NSTK), an AEA analogue synthesized by this laboratory was reported to exert significant efficacy through multiple interventions. Within this study, the amyloid precursor protein (APP)SWE/presenilin-1 (PS1)M146V/TauP301L mouse (3Tg-AD) model was used to explore further the neuroprotective effects of NSTK and its underlying mechanisms. NSTK could increase spontaneous locomotor activity in the open field and low anxiety-like behavior in the elevated plus maze, and improve the spatial memory deficits in the Morris water maze. The biochemical analysis suggested that NSTK could decrease Ab42 deposition, abnormal tau aggregation, and the expressions of p-APP Thr668, PS1 and p-tau Ser202/Thr205 in the hippocampus of 3Tg-AD mice. Consistently, NSTK could reduce the level of malondialdehyde, increase the activity of superoxide dismutase and catalase. Up-regulation of Bcl-2, and down-regulation of BAX, caspase-3 and inflammatory cytokines also occurred in the hippocampus of 3Tg-AD mice after treatment with NSTK. Thus, NSTK could intervene in multiple pathological processes of AD and would be a drug candidate against AD.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Small Molecule
Therapeutic Agent:
Dipotassium N-stearoyltyrosinate (NSTK)
Therapeutic Target:
Cannabinoid Receptor 1 (CB1)
Therapeutic Target:
Cannabinoid Receptor 2 (CB2)

Animal Model

Model Information:
Species:
Mouse
Model Type:
Non-transgenic
Strain/Genetic Background:
C57BL/6J
Species:
Mouse
Model Type:
APPxPS1xTau
Strain/Genetic Background:
Not Reported

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest

Outcomes

Outcome Measured
Outcome Parameters
Behavioral
Morris Water Maze
Open Field Test
Elevated Plus Maze
Histopathology
Tau Pathology
beta Amyloid Deposits
beta Amyloid Load
Biochemical
Brain-beta Amyloid Peptide 42
phospho-Amyloid Precursor Protein (phospho-APP)
phospho-Tau
Superoxide Dismutase (SOD)
Catalase (CAT)
Bcl-2
Bax
Caspase Activation
Proinflammatory Cytokines
Caspase 3
Oxidative Stress Markers
Presenilin 1 (PS1)
Interleukin 1 beta (IL-1 beta)
Interleukin 6 (IL-6)
Tumor Necrosis Factor alpha (TNF alpha)
Total Tau Protein
Immunochemistry
Brain-beta Amyloid Peptide 42
phospho-Tau